BRAF Inhibitors (e.g., Vemurafenib, Dabrafenib)

Type: drug

Status: Investigational (for ameloblastoma), FDA Approved (for melanoma)

Developer: Genentech (Vemurafenib), Novartis (Dabrafenib)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026